GlassScriptPhysician profile
James R Kimberly
NPI 1528240199
$11,041.90
in general payments reported to CMS, 2019-2025
40 companies · $3,685 in 2025
The $3,685 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $332 · 2021: $701 · 2022: $1,008 · 2023: $1,672 · 2024: $2,544 · 2025: $3,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,883 · Education: $17.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,883.49 |
| Education | $17.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,434.54 | 2019-2025 | |
| Janssen Biotech, INC. | $1,277.08 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,070.49 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $957.54 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $628.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $462.99 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $320.62 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $256.09 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $220.39 | 2020-2024 | Linzess |
| Celgene Corporation | $208.60 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $201.52 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $197.49 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $186.05 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $182.05 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $168.74 | 2025 | Iqirvo |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kimberly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.